DrugPatentWatch Database Preview
Binimetinib - Generic Drug Details
What are the generic drug sources for binimetinib and what is the scope of freedom to operate?
Binimetinib
is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Binimetinib has two hundred and two patent family members in fifty-one countries.
One supplier is listed for this compound.
Summary for binimetinib
| International Patents: | 202 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 66 |
| Clinical Trials: | 37 |
| Patent Applications: | 162 |
| DailyMed Link: | binimetinib at DailyMed |
Recent Clinical Trials for binimetinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hospices Civils de Lyon | N/A |
| University of California, San Francisco | Phase 1/Phase 2 |
| UNICANCER | Phase 2 |
Synonyms for binimetinib
| 181R97MR71 |
| 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide |
| 5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami |
| 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide |
| 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| 606143-89-9 |
| A11493 |
| AB0095018 |
| AC-29023 |
| ACWZRVQXLIRSDF-UHFFFAOYSA-N |
| AK175886 |
| AKOS026750517 |
| AOB2072 |
| ARRY 162 |
| ARRY 438162 |
| ARRY-162 |
| ARRY-162,MEK-162 |
| ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162 |
| ARRY-438162 |
| AS-16706 |
| BC600594 |
| BCP06780 |
| Binimetinib (JAN/USAN) |
| Binimetinib (MEK162, ARRY-162, ARRY-438162) |
| Binimetinib [USAN:INN] |
| Binimetinib;MEK-162; ARRY-162;ARRY-438162 |
| C17H15BrF2N4O3 |
| cas:606143-89-9;MEK162 |
| CHEMBL3187723 |
| CS-0627 |
| D10604 |
| DB11967 |
| DTXSID70209422 |
| EX-A1024 |
| FT-0697088 |
| GTPL7921 |
| HMS3652J14 |
| HY-15202 |
| J-516581 |
| KS-0000062X |
| MEK-162 |
| MEK162 |
| MEK162 (ARRY-162, ARRY-438162) |
| MEK162 (Arry-162) |
| MEK162(Binimetinib) |
| Mektovi |
| MFCD22124525 |
| MLS006011180 |
| NCGC00345804-01 |
| NCGC00345804-10 |
| NVP-MEK162 |
| QCR-138 |
| RL04283 |
| s7007 |
| SB16501 |
| SCHEMBL570088 |
| SMR004702949 |
| SW219910-1 |
| UNII-181R97MR71 |
| W-5894 |
| Y1468 |
| ZINC38460704 |
US Patents and Regulatory Information for binimetinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Pricing | See Pricing | Y | Y | See Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for binimetinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Serbia | 55568 | See Pricing |
| European Patent Office | 2130537 | See Pricing |
| Tunisia | 2012000081 | See Pricing |
| Canada | 2537098 | See Pricing |
| Singapore | 2013013339 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for binimetinib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2727918 | CA 2019 00013 | Denmark | See Pricing | PRODUCT NAME: KOMBINATION AF BINIMETINIB OG ENCORAFENIB, I ALLE FORMER HVERT ISAER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1315 ELLER EU/1/18/1314 20180924 |
| 2470526 | 300973 | Netherlands | See Pricing | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
| 2470526 | PA2019005 | Lithuania | See Pricing | PRODUCT NAME: ENKORAFENIBAS BET KOKIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA; REGISTRATION NO/DATE: EU/1/18/1314 20180920 |
| 2727918 | 300975 | Netherlands | See Pricing | PRODUCT NAME: COMBINATIE VAN BINIMETINIB EN ENCORAFENIB, BEIDE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/18/1314 20180924 |
| 1482932 | LUC00100 | Luxembourg | See Pricing | PRODUCT NAME: MEKTOVI - BINIMETINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
